- Joseph M. Limber - Chair
- Martyn Coombs - Director
- Campbell Murray, MD - Director
- K. Leonard Judson - Director
- Anna M. Wu, PhD - Co-Founder and Chief Scientific Advisor
- Thilo Schroeder, PhD - Director
- François Valencony - Director
- Jeff Bailey - Director
Mr. Limber has 34 years of experience in all aspects of the management and financing of pharmaceutical and biotechnology companies. He served as president and CEO of Prometheus Laboratories, Inc. overseeing business operations and commercial strategies of the company's diagnostics and pharmaceutical products for personalized clinical management. Prior to his time at Prometheus, Mr. Limber served as president and CEO of Aclara BioSciences, Inc. During his tenure at Aclara, Limber raised approximately $250 million through strategic collaborations, private placements, and the company’s IPO. Mr. Limber also served as president and CEO at Praecis Pharmaceuticals, Inc., and held senior business development, and commercial positions with Sequus Pharmaceuticals (now Johnson & Johnson), Syntex Corporation (now Roche) and Ciba-Geigy Corporation (now Novartis), thus rounding out his established career. Mr. Limber has also held seats on the Boards of Directors at Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals, and CombiMatrix Corporation. Mr. Limber received a BA in Liberal Arts from Duquesne University.
Mr. Coombs is a recognized Industry Leader in Nuclear Medicine and Imaging. Most recently, as President of Jubilant DraxImage, he led the company through a period of rapid organic growth, tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill®, a key PET Cardiology product. Mr. Coombs has held senior leadership roles at Amersham (now GE Healthcare), and Nihon Medi-Physics, where he was the number two Executive. Previously, he has served as CEO of Asterand PLC, a public life sciences company, where in 2008 he received an award from The Financial Times for the top performing stock on the London Stock Exchange, out of more than 2,000 companies. He has lived and worked in North America, Japan, and Europe. Mr. Coombs holds a degree in Mathematics, and an MBA with distinction from Warwick Business School.
Dr. Campbell Murray is a managing director of the Novartis Venture Fund based in Boston, MA. Prior to joining the fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects and as a physician in Auckland, New Zealand. Campbell is a New Zealand trained physician, Kauffman Fellow, and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio Therapeutics, Akebia Therapeutics, Alios BioPharm, Euthymics Biosciences, Galera, Neurovance and Tokai Pharmaceuticals and as an observer on the board of Aileron Therapeutics.
K. Leonard Judson is the President and Managing Director of Cycad Group. Prior to co-founding Cycad Group in 2000, he practiced law for 14 years and was a partner in two law firms including May, Potenza, Judson and Baran, P.C. where he served as its CEO until his departure to the Cycad Group. Throughout his legal career a substantial portion of his practice was devoted to representing both entrepreneurs and investors in various aspects corporate law, finance, mergers and acquisitions. Leveraging upon his experience interning for the SEC and his subsequent securities law practice, Leonard was as a member of the NASD Board of Arbitrators from 1989 to 2002 and chaired numerous securities industry related arbitrations. Among his responsibilities at Cycad Group, Leonard currently serves as a Director or observer to the board of directors of several of Cycad Group’s portfolio companies including, ImaginAb, Nanosteel Corporation, Sofie Biosciences, and Lixivia. Leonard is also a Director and the Executive Vice President of the Glenn Foundation For Medical Research, Inc., a non-profit foundation supporting basic research to understand the biology of aging with the objective of developing interventions to extend the healthy years of human life. Leonard holds a J.D. with Honors, from George Washington University, Washington, D.C., and a B.S. degree, Cum Laude, from Northern Arizona University.
Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors. He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
Founder and Chief Scientific Advisor
Dr. Anna Wu is a Professor in the Department of Molecular and Medical Pharmacology and a Professor in Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA. Previously, Dr. Wu was a Professor of Molecular Biology at the Beckman Research Institute of the City of Hope in Duarte, CA. Dr. Wu is a respected leader in molecular imaging who currently serves as the Director of the Cancer Molecular Imaging Program in the Jonsson Comprehensive Cancer Center at UCLA. She also served as President and is currently a Fellow of the World Molecular Imaging Society. As an acknowledged expert in engineered antibodies for cancer targeting, Dr. Wu’s research is the foundation of ImaginAb’s technology. Dr. Wu received her A.B. in Biochemical Sciences from Harvard University and a PhD in Molecular Biophysics and Biochemistry from Yale University.
General Manager Mérieux Développement, President MxD North America LLC
Francois Valencony started his career in Chicago, IL for Schneider Electric, supporting several acquisitions and growth projects for the North American and South American divisions until 2000. He then actively participated in the development of a start-up software company in London, UK, subsequently acquired by Descartes group. François has been working for Institut Mérieux since 2003, leading several transactions within the diagnostic and biotech business areas, including global out-licensing agreements and acquisitions. Operational responsibilities included the set-up of the first research center of bioMérieux in China and the management of five vaccine programs. Francois is currently General Manager of Mérieux Développement and President of MxD North America. François graduated from HEC in Paris and holds a Master Degree from CEMS in Köln, Germany.
Mr. Bailey brings 30 years of healthcare experience across diverse functional areas including supply chain, commercial, R&D, Business Development, and Finance. He most recently served as President and CEO of Lantheus Medical Imaging and led the organization through a successful transformation, culminating in an IPO. Additionally, Mr. Bailey has played key roles resulting in strategic transactions with the Fougera Pharmaceuticals acquisition by Novartis, where he served as the Fougera COO, as well as the King Pharmaceuticals acquisition by Pfizer, where he served as the King Chief Commercial Officer. Prior to King, he served as President and General Manager of an Operating Unit at Novartis. Mr. Bailey began his career at Johnson & Johnson serving in multiple roles across supply chain, commercial and general management with several operating companies, including Janssen Pharmaceutica. He holds BA in Business Administration from Rutgers University. Mr. Bailey also serves as an independent board member of Landauer, an NYSE-listed company.